Citadel Advisors
SGMT icon

Citadel Advisors’s Sagimet Biosciences SGMT Stock Holding History

Citadel Advisors’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$809K Buy
104,633
+36,460
+53% +$248K ﹤0.01% 8728
2026
Q1 		$356K Buy
68,173
+5,054
+8% +$28.2K ﹤0.01% 10083
2025
Q4 		$374K Buy
63,119
+53,078
+529% +$381K ﹤0.01% 9679
2025
Q3 		$68.9K Sell
10,041
-92,742
-90% -$752K ﹤0.01% 12045
2025
Q2 		$783K Buy
102,783
+59,815
+139% +$252K ﹤0.01% 7612
2025
Q1 		$140K Sell
42,968
-701,564
-94% -$2.94M ﹤0.01% 10981
2024
Q4 		$3.35M Sell
744,532
-471,339
-39% -$2.39M ﹤0.01% 4651
2024
Q3 		$3.37M Buy
1,215,871
+20,876
+2% +$64.3K ﹤0.01% 4591
2024
Q2 		$4.09M Buy
1,194,995
+1,164,729
+3,848% +$5.34M ﹤0.01% 4065
2024
Q1 		$164K Buy
+30,266
New +$217K ﹤0.01% 10630
2023
Q4 		– Sell
-311,634
Closed -$2.74M – 15143
2023
Q3 		$2.74M Buy
+311,634
New +$4.15M ﹤0.01% 4642

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors's SGMT Position: Q2 2026 in Review

Citadel Advisors increased its Sagimet Biosciences (SGMT) stake by 53% in Q2 2026, buying an estimated $248K and bringing the position to 104,633 shares worth $809K. The position accounts for ﹤0.01% of the portfolio, ranked #8728.

Citadel Advisors first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $4.09M in Q2 2024. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Citadel Advisors held 104,633 shares of Sagimet Biosciences worth $809K as of Q2 2026.
  • Citadel Advisors bought 36,460 Sagimet Biosciences shares in Q2 2026, an estimated $248K.
  • Sagimet Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8728 holding.
  • Citadel Advisors first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • Citadel Advisors's Sagimet Biosciences position peaked at $4.09M in Q2 2024.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.